FGFR4 and neoplasm: While the FGFR4 inhibitor BLU-554 or the METTL16 GapmeR ASO alone was able to inhibit CCA cell growth, we found that combinational use of both the FGFR4 inhibitor BLU-554 and the METTL16 GapmeR ASO exhibited more tumor inhibitory effect (Fig. 6G).